Docetaxel in ovarian cancer

Bibliography

• BISSERY M-C, NOHYNEK G, SANDERINK G-J, LAVELLE F: Docetaxel (Taxoteren: a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs (1995) 6:339–355.
   PubMed Web of Science ®Google Scholar
• RINGEL I, HORWITZ SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. j Nat. Cancer Inst. (1991) 83:288–291.
   PubMed Web of Science ®Google Scholar
• NOGALES E, WOLFF SG, DOWNING KH: Structure of the cifi tubulin dimmer by electron crystallography. Nature (1998) 391:199–202.
   PubMed Web of Science ®Google Scholar
• HALDAL S, BASU A, CROCE CM: Bc12 is the guardian of microtubule integrity. Cancer Res. (1997) 57:229–233.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, ABELG: Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol (1992) 30(6):444–450.
   PubMed Web of Science ®Google Scholar
• BOLLAG DM, MCQUEENEY PA, ZHU J et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55:2325–2333.
   PubMed Web of Science ®Google Scholar
• UYAR D, TAKIGAWA N, MEKHAIL T et al.: Apoptotic pathways of epothilone BMS 310705. Gynecol. Oncol (2003) 91:173–178.
   PubMed Web of Science ®Google Scholar
• HORWITZ SB: Mechanism of action of taxol. Trends PharmacoL Sci. (1992) 13:134–136.
   PubMed Web of Science ®Google Scholar
• KEATES RAB, SARANGI F, LING V: Structural and functional alterations in microtubule protein from Chinese hamster ovary cell mutants. Proc. Nat. Acad. Sci. USA (1981) 78:5638–5642.
   PubMed Web of Science ®Google Scholar
• DUMONTET C, DURAN GE, STEGER KA, BEKETIC-ORESKOVIC L, SIKIC BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. (1996) 56:1091–1097.
   PubMed Web of Science ®Google Scholar
• KRUH GD, BELINSKY MG: The MRP family of drug efflux pumps. Oncogene (2003) 22:7537–7552.
   PubMed Web of Science ®Google Scholar
• HOPPER-BORGE E, CHEN ZS, SHCHAVELEVA I, BELINSKY MG, KRUH GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. (2004) 64:4927–4930.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, BALL H et al.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. Clin. Oncol (1994) 12:1748–1753.
   Web of Science ®Google Scholar
• MCGUIRE WP, BLESSING JA, BOOKMAN MA et al.: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecological Oncology Group study. Clin. Oncol (2000) 18:1062–1067.
   Web of Science ®Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K, KULP B, PETERSON G, BELINSON J: Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J. Cancer Res. Clin. Oncol (1998) 124(0:326–328.
   PubMed Web of Science ®Google Scholar
• AAPRO MS: Docetaxel (Taxotere): a highly active taxoid with manageable toxicity. Semin. Oncol (1995) 22(2 Suppl. 4):1–2.
   Google Scholar
• PICCART MJ, GORE M, TEN BOKKEL HUININK W et al.: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Nat. Cancer Inst. (1995) 87:676–681.
   PubMed Web of Science ®Google Scholar
• FRANCIS P, SCHNEIDER J, HANN L et al.: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. Clin. Oncol (1994) 12:2301–2308.
   Web of Science ®Google Scholar
• KAVANAGH JJ, KUDELKA AP, DE LEON CG et al.: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. (1996) 2:837–842.
   Google Scholar
• KAYE SB, PICCART M, AAPRO M, FRANCIS P, KAVANAGH J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur. J. Cancer (1997) 33:2167–2170.
   PubMed Web of Science ®Google Scholar
• FUJI WARA K, KOHNO I, TANAKA K et al.: Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group. Anticancer Res. (1999) 19:639–644.
   PubMed Web of Science ®Google Scholar
• NIWA Y, NAKANISHI T, KUZUYA K et al.: Salvage treatment with docetaxel for recurrent epithelial ovarian cancer Int. J. Clin. Oncol (2003) 8:343–347.
   Google Scholar
• KATSUMATA N, TSUNEMATSU R, TANAKA K et al.: A Phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann. Oncol (2000) 11:1531–1536.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV: Second-line chemotherapy for non-small-cell lung cancer. Curr. Oncol. Rep. (2000) 2(1):96–101.
   PubMedGoogle Scholar
• UNTCH M, UNTCH A. SEWN BU et al.: Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs. (1994) 5(1):24–30.
   Google Scholar
• VALERO V JONES SE, VON HOFF DD et al.: A Phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol (1998) 16:3362–3368.
   Google Scholar
• VERSCHRAEGEN CF, SITTISOMWONG T, KUDELKA AP et al.: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J. Clin. Oncol (2000) 18:2733–2739.
   PubMed Web of Science ®Google Scholar
• ROSE PG, BLESSING JA, BALL HG et al.: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2003) 88:130–135.
   PubMed Web of Science ®Google Scholar
• DIERAS V GUASTALLA JP, FERRERO JM et al.: A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study. Cancer Chemother. Pharmacol (2004) 53:489–495.
   PubMed Web of Science ®Google Scholar
• PFISTERER J, DU BOIS k WAGNER U et al.: Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol. Oncol (2004) 92:949–956.
   Google Scholar
• MARKMAN M, KENNEDY k WEBSTER K et al.: Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J. Clin. Oncol (2001) 19:1901–1905.
   Google Scholar
• VASEY PA, JAYSON GC, GORDON A et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Nat. Cancer Inst. (2004) 96(22):1682–1691.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML: CPT-11: an original spectrum of clinical activity. Semin. Oncol (1996) 23\(Suppl. 3):21–6.
   Google Scholar
• ROTHENBERG ML: Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist (2001) 6:66–80.
   PubMed Web of Science ®Google Scholar
• KUNIMOTO T, NITTA K, TANAKA T et al.: Antitumor activity of 7-ethyl- 10[441-piperichno)]carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. (1987) 47:5944–5947.
   PubMed Web of Science ®Google Scholar
• ESCOBAR PF, MARKMAN M, ROSE P, ZANOTTI K, WEBSTER K, BELINSON J: Phase II trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol (2004) 92:192–196.
   PubMed Web of Science ®Google Scholar
• MAENPAA JU, HAGMAN E, KIVINEN S, POHTO M, KAAR K, JEKUNEN k The combination of Taxoteres (T) and Camptos (C) for second line treatment of ovarian cancer - a Phase I dose-finding multicentre study (Abstr). Ann. Oncol (1998) 9\(Suppl. 4):334.
   Google Scholar
• MAENPAA JU, KAAR K, KIVINEN S, POHTO M, JEKUNEN A: Docetaxel and CPT-11 for recurrent ovarian cancer - a Phase II study. Proc. Am. Soc. Clin. Oncol. (1999) 18:Abstr. 1403.
   Google Scholar
• OULID-AISSA D, BRUNO R, LEBECQA et al.: Taxotere safety in patients with impaired liver function (le. Proc. ASCO (1996) 15:476a(1508a).
   Google Scholar
• MARKMAN M, HOSKINS W: Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol (1992) 10:513–514.
   PubMed Web of Science ®Google Scholar
• ROSE PG, SMREKAR M: Improvement ofpaclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol. Oncol. (2003) 91:423–425.
   PubMed Web of Science ®Google Scholar
• RIGGS JE, ASHRAF M, SNYDER RD, GUTMANN L: Prospective nerve conduction studies in cisplatin therapy. Ann. NeuroL (1988) 23:92.
   PubMed Web of Science ®Google Scholar
• FAZIO R, QUATTRINI A, BOLOGNESI A et al.: Docetaxel neuropathy: a clinical and morphological study./ Peripher. Nerv. Syst (1999) 4:69.
   Google Scholar
• DELLON AL, SWIER P, MALONEY CT JR, LIVENGOOD MS, WERTER S: Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves. Plast. Reconsm. Surg (2004) 114:478–483.
   PubMed Web of Science ®Google Scholar
• MOON C, VERSCHRAEGEN CF, BEVERS M et al.: Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs (2000) 11:565–568.
   PubMed Web of Science ®Google Scholar
• TERAUCHI F, HIRANO T, TAOKA H et al.: Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int J. Clin. Oncol (2003) 8:348–351.
   PubMedGoogle Scholar
• BERKENBLIT A. SEIDEN MV, MATULONIS UA et al.: A Phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. (2004) 95(3):624–631.
   Google Scholar
• ESMAELI B, VALERO V AHMADI BOOSER D: Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology (2001) 108:994–995.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, LIU PY, WILCZYNSKI S et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecological Oncology Group trial. J. Clin. Oncol (2003) 21(13):2460–2465.
   PubMed Web of Science ®Google Scholar
• PARMAR MK, LEDERMANN JA, COLOMBO N et al.: Paditaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 361(9375):2099–2106.
   Google Scholar
• GONZALEZ-MARTIN AA, CALVO E, BOVER I et al.: Randomized phase II study of carboplatin (C) versus paclitaxel-carboplatin (CP) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): A GEICO study (Spanish Group for Investigation on Ovarian Carcinoma). Proc. Am. Soc. Clin. Oncol (2003):451 (Abstr. 1812).
   Google Scholar